When was Ilex Oncology founded?
Ilex Oncology was founded in 1992.
Where is Ilex Oncology's headquarters?
Ilex Oncology's headquarters is located at 4545 Horizon Hill Boulevard, San Antonio.
What is Ilex Oncology's latest funding round?
Ilex Oncology's latest funding round is Acq - P2P.
How much did Ilex Oncology raise?
Ilex Oncology raised a total of $26.85M.
Who are the investors of Ilex Oncology?
Investors of Ilex Oncology include Genzyme, Childrens Medical Center, SMALLCAP World Fund, Franklin Templeton, Paramount Capital Asset Management and 26 more.
Who are Ilex Oncology's competitors?
Competitors of Ilex Oncology include Kiadis Pharma, Charleston Laboratories, InClinica, Activate Immunotherapy, Neuraltus Pharmaceuticals and 15 more.
You May Also Like
Unibioscreen is a specialist oncology discovery & development company, with focus on 'first in class' drugs, mainly of natural origin. Unibioscreen has successfully developed 2 drug candidates from discovery to clinical development in cancer patients and has other promising pre-clinical compounds in its pipeline.
Esperance Pharmaceuticals develops targeted anticancer drugs that selectively kill cancer cells without harming normal cells.
Morria's lead products are first-in-class synthetic anti-inflammatory drugs termed Multi-Functional Anti-Inflammatory Drugs (MFAID). These drugs target a known but previously elusive key event in the inflammation process upstream of current competitors while simultaneously protecting cells and tissues against inflammatory damage and stimuli. Morria has two lead products (MRX4 for allergic rhinitis and MRX6 for contact dermatitis) scheduled for clinical trials in late 2007 and a growing library of additional compounds. Double blind placebo controlled human pilot-studies for contact dermatitis have been successfully completed in Israel .nMorria is also currently engaged in research agreements with three global pharmaceutical leaders in the fields of ophthalmology, eye-care and cardiovascular medicine.
InClinica, formerly IndiPharm, is a global clinical CRO that specializes in leading companies through clinical trials, and works across all phases of clinical development, with a particular strength in assisting small to mid-sized companies.
Appian aims to provide consulting and operational support in pharmaceutical product development. The company grew out of the contract pharmaceutical research industry. Dr. Grier Harris, Appian's President, has worked in clinical trials since 1986 in most areas within the industry - from basic medical research to large scale international clinical trials.
The company's current portfolio of compounds and technologies in the development pipeline includes: i) A0001, Ophthalmic Dye for Retinal Surgery ii) A0003, treatments for Age-related Macular Degeneration (AMD). and iii)A0006 . Company is in negotiations to acquire rights to a Phase II program by year end 2007. The following diagram summarizes the important existing and anticipated clinical development milestones for each of the programs as they relate to their respective targeted applications:
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.